क्या है Semaglutide? एक शोध अवलोकन

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a compound that mimics the naturally occurring incretin hormone GLP-1 to regulate blood sugar levels, reduce appetite, and slow gastric emptying. Originally developed by Novo Nordisk for the treatment of type 2 diabetes, semaglutide has become one of the most widely studied and prescribed compounds in metabolic medicine. It is available in both injectable (Ozempic®, Wegovy®) and oral (Rybelsus®) formulations, making it one of the few peptide-based therapeutics with a viable oral delivery option.

GLP-1 is an incretin hormone naturally produced in the L-cells of the small intestine in response to food intake. It signals the pancreas to release insulin, suppresses glucagon secretion, and communicates with the brain to promote satiety. However, native GLP-1 has a half-life of only about 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered with structural modifications — including a fatty acid side chain that enables albumin binding — that extend its half-life to approximately 7 days, allowing for once-weekly dosing.

How Does Semaglutide Work?

Semaglutide binds to and activates GLP-1 receptors, which are expressed in multiple tissues including the pancreatic beta cells, the hypothalamus, the gastrointestinal tract, and the cardiovascular system. This multi-tissue receptor expression accounts for semaglutide's wide-ranging physiological effects.

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion — meaning it enhances insulin release primarily when blood glucose is elevated, reducing the risk of hypoglycemia compared to some other diabetes medications. Simultaneously, it suppresses glucagon release from pancreatic alpha cells, which further reduces hepatic glucose output.

In the brain, semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem nuclei involved in appetite regulation. Research has shown it reduces hunger signaling, increases feelings of fullness after eating, and may reduce food cravings — particularly for high-fat, energy-dense foods. In the gastrointestinal tract, semaglutide slows gastric emptying, which contributes to prolonged satiety after meals and helps moderate postprandial blood glucose spikes.

Key Research Findings

Trial/Study	Population	Key Finding	Year
SUSTAIN 6	Type 2 diabetes	26% reduction in major adverse cardiovascular events (MACE)	2016
STEP 1	Obesity (non-diabetic)	Average 14.9% body weight reduction at 68 weeks	2021
STEP 2	Obesity with type 2 diabetes	Average 9.6% body weight reduction at 68 weeks	2021
SELECT	Overweight/obese with CVD	20% reduction in MACE regardless of diabetes status	2023
FLOW	Type 2 diabetes with CKD	Significant reduction in kidney disease progression	2024

Common Research Applications

• Type 2 diabetes management: Semaglutide is a first-line injectable option for glycemic control, demonstrating superior HbA1c reductions compared to many standard treatments.
• Chronic weight management: At higher doses (2.4 mg weekly), semaglutide has shown some of the largest weight reductions observed with pharmacotherapy in clinical trials.
• Cardiovascular risk reduction: The SELECT trial established cardiovascular benefit independent of diabetes status, expanding its research relevance beyond metabolic indications.
• Renal protection: Emerging data from the FLOW trial suggests kidney-protective effects in patients with type 2 diabetes and chronic kidney disease.
• Neurological research: Early-stage investigations are exploring GLP-1 receptor agonism for neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease.

How Does Semaglutide Compare?

Semaglutide is most frequently compared to tirzepatide, a newer dual GIP/GLP-1 receptor agonist. While semaglutide targets only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which may account for its somewhat greater weight loss observed in head-to-head trials. Both compounds represent significant advances in metabolic pharmacology. For a detailed comparison, see our semaglutide vs. tirzepatide comparison article. Semaglutide also compares favorably to older GLP-1 receptor agonists like liraglutide, offering longer duration of action and greater efficacy in most clinical endpoints.

Safety and Considerations

The most common side effects reported in clinical trials are gastrointestinal in nature: nausea, vomiting, diarrhea, and constipation. These effects are typically most pronounced during dose escalation and tend to diminish over time. More serious but rarer considerations include pancreatitis, gallbladder events, and a boxed warning regarding medullary thyroid carcinoma risk based on rodent studies (though human relevance is unclear). Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. All prescribing and use should be under the supervision of a qualified healthcare provider. This information is for educational purposes only and does not constitute medical advice.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide as the active ingredient but are approved for different indications and at different doses. Ozempic (up to 2.0 mg weekly) is approved for type 2 diabetes management, while Wegovy (2.4 mg weekly) is approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

How does oral semaglutide (Rybelsus) work?

Rybelsus uses a co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), an absorption enhancer that protects semaglutide from gastric degradation and facilitates its absorption through the stomach lining. It must be taken on an empty stomach with a small amount of water, and patients must wait at least 30 minutes before eating.

Is semaglutide a peptide?

Yes, semaglutide is a modified peptide. Its backbone is based on the 31-amino-acid sequence of human GLP-1 (with amino acid substitutions at positions 8 and 34), and it includes a C-18 fatty diacid chain attached via a linker at position 26. These modifications protect it from DPP-4 degradation and enable albumin binding, extending its half-life from minutes to approximately one week.